Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-center, Open and Single-dose Clinical Trial to Explore the Body Mass Balance of Oral Suspension of 300 mg /100 μCi [14C] Sulfatinib in Chinese Adult Male Healthy Volunteers

Trial Profile

Single-center, Open and Single-dose Clinical Trial to Explore the Body Mass Balance of Oral Suspension of 300 mg /100 μCi [14C] Sulfatinib in Chinese Adult Male Healthy Volunteers

Completed
Phase of Trial: Phase 0

Latest Information Update: 06 Feb 2019

At a glance

  • Drugs Sulfatinib (Primary)
  • Indications Biliary cancer; Neuroendocrine tumours; Solid tumours; Thyroid cancer
  • Focus Pharmacokinetics
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 21 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top